Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553101 | 0.85 | SLC6A2 (0.48) | CYP2D6CHRM2CHRM1HRH3OGA | |
| SCHEMBL20832756 | 0.77 | SLC6A2 (0.48) | CYP2D6CHRM2CHRM1OGA | |
| SCHEMBL22227886 | 0.77 | SLC6A2 (0.48) | CYP2D6CHRM2CHRM1OGA | |
| SCHEMBL6450241 | 0.76 | CYP2D6 (0.45) | CYP2D6CHRM2CHRM1HRH3 | |
| SCHEMBL5553174 | 0.76 | CYP2D6 (0.41) | PTGS2CYP2D6CHRM2CHRM1ACHE | |
| SCHEMBL6447434 | 0.76 | CYP2D6 (0.41) | CYP2D6CHRM2CHRM1ACHEHRH3 | |
| SCHEMBL5555136 | 0.76 | DPP4 (0.53) | ADAMTS4CYP2D6MGLLCHRNB4CHRNA3 | |
| SCHEMBL6445690 | 0.76 | DPP4 (0.53) | ADAMTS4CYP2D6MGLLCHRNB4CHRNA3 | |
| SCHEMBL6448616 | 0.75 | DRD2 (0.45) | ADAMTS4CYP2D6HRH3 | |
| SCHEMBL5549345 | 0.74 | ACHE (0.49) | ACHEHRH3OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756058-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105744-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. | 2005-11-10 | — | — | WO | claimed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | claimed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245543-A1 | Histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | PRKCI 4493/4885PTGS2 2955/4885ADAMTS4 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.